Takeda Pharmaceutical Company Limited (TAK) earnings: date, estimates, results and stock reactions
Next earnings: Q3 FY2026 on 2027-01-28 (expected, after the close). EPS estimate 44.59, revenue estimate 1.20T.
Over the last 12 reports the stock moved 2.3% on average (either way), rising 6 times and falling 6. EPS beat estimates 8 of 12 times; revenue 8 of 12. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).
| Quarter | Reported | EPS | EPS estimate | EPS surprise | Revenue | Revenue estimate | Stock move |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-10-29 | 121.29 | 45.38 | +167.3% | 1.19T | 1.16T | +5.5% |
| Q1 FY2026 | 2026-07-30 | 71.65 | 53.12 | +34.9% | 1.22T | 1.15T | -5.7% |
| Q4 FY2025 | 2026-05-13 | -15.58 | -24.04 | +35.2% | 1.10T | 1.12T | +1.7% |
| Q3 FY2025 | 2026-01-29 | 64.93 | 43.14 | +50.5% | 1.18T | 1.19T | +3.1% |
| Q2 FY2025 | 2025-10-29 | -8.16 | 21.61 | -137.8% | 1.11T | 1.21T | -1.0% |
| Q1 FY2025 | 2025-07-29 | 81.38 | 50.79 | +60.2% | 1.11T | 1.20T | -0.2% |
| Q4 FY2024 | 2025-05-07 | -64.14 | -8.59 | -646.6% | 1.05T | 1.04T | -3.1% |
| Q3 FY2024 | 2025-01-30 | 14.92 | 25.86 | -42.3% | 1.14T | 1.12T | +1.3% |